Treatment of smoldering multiple myeloma with iberdomide and dexamethasone

Iberdomide in Intermediate- and High-Risk Smoldering Myeloma (SMM) Patients: A Phase 2 Study With a Safety Run-in

This study is testing if a new treatment combining iberdomide and dexamethasone can help people with smoldering multiple myeloma live longer and feel better.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 68 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Emory University (Academic / other)
• Drugs / interventions: prednisone, Immunotherapy
• Locations: 1 site (Atlanta, Georgia)
• Trial ID: NCT04776395 on ClinicalTrials.gov

What this trial studies

This phase II trial investigates the effects of iberdomide, both alone and in combination with dexamethasone, on patients with intermediate- or high-risk smoldering multiple myeloma. The study aims to determine the overall response rate and progression-free survival rates, as well as the time to progression and overall survival for participants. Additionally, it will assess the safety profile of the treatments and explore the impact of iberdomide on immune cell activity and minimal residual disease. The trial includes quality-of-life assessments to evaluate patient experiences during treatment.

Who should consider this trial

Good fit: Ideal candidates are individuals diagnosed with intermediate- or high-risk smoldering multiple myeloma within the last five years.

Not a fit: Patients with low-risk smoldering multiple myeloma or those who do not meet the specific eligibility criteria may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could improve progression-free survival and overall outcomes for patients with smoldering multiple myeloma.

How similar studies have performed: Other studies have shown promising results with immunotherapy approaches in multiple myeloma, suggesting potential for success with this treatment strategy.

Eligibility criteria

Inclusion Criteria:

* Subject must have intermediate- or high risk smoldering multiple myeloma (SMM) as confirmed by at least one of the following factors either at screening or within 28 days of screening:

  * Bone marrow clonal plasma cells \>= 20% confirmed on either screening bone marrow biopsy or by outside pathology ≤5 years from initiation of study drug.
  * Abnormal serum free light chain ratio \> 20 by serum free light chain (FLC) assay
  * Serum monoclonal protein \>= 2 g/dL
* Subject must have been diagnosed with SMM =\< 5 years from initiation of study drug
* Both men and women of all races and ethnic groups are eligible for this study
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnofsky \>= 60%) is required for eligibility
* Absolute neutrophil count (ANC) \>= 1500/uL
* Hemoglobin (Hgb) \> 11 g/dL
* Platelet count \>= 100,000 cells/mm\^3 and must be platelet and packed red blood cells (PRBC) transfusion independent with no granulocyte colony-stimulating factor (G-CSF) to ensure eligibility within 8 weeks of screening
* Estimated creatinine clearance \>= 30 mL/min as defined by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) or Cockcroft-Gault
* Total bilirubin \< 2 mg/dL except in subjects with congenital bilirubinemia such as Gilbert syndrome, in which case direct bilirubin =\< 2 times the institutional upper limit of normal is required
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 2.5 times the institutional upper limit of normal
* Left ventricular ejection fraction \>= 40%
* Females of childbearing potential (FCBP) must have two negative pregnancy tests as verified by the investigator prior to starting study treatment. The effects of Iberdomide on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment. This applies even if the subject practices true abstinence from heterosexual contact. A FCBP must either commit to true abstinence from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with two forms of contraception: one highly effective, and one additional effective (barrier) measure of contraception without interruption 28 days prior to starting investigational product, during the study treatment (including dose interruptions), and for at least 28 days after the last dose of iberdomide. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
* Female of childbearing potential (FCBP) is a sexually mature woman who:

  * Has not undergone a hysterectomy or bilateral oophorectomy; or
  * Has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
* The subject must be willing to comply with fertility requirements as below:

  * Male subjects must agree to use an adequate method of contraception for the duration of the study and for 3 months afterwards
  * Female subjects must be either postmenopausal, free from menses \>= 2 years (yrs), surgically sterilized, willing to use two adequate barrier methods of contraception to prevent pregnancy, or agree to abstain from heterosexual activity starting with screening and for 3 months after last treatment in all patients
  * Patients must agree not to donate blood, sperm/ova while taking protocol therapy and for at least 4 weeks after stopping treatment
* Subject must understand and voluntarily sign an informed consent form (ICF) prior to any study-related assessments/procedures being conducted
* Subject is willing and able to adhere to the study visit schedule and other protocol requirements
* Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

Exclusion Criteria:

* Multiple myeloma requiring treatment as defined by SLiM-CRAB criteria
* Monoclonal gammopathy of undetermined significance (MGUS), polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS syndrome), plasma cell leukemia, primary systemic light chain (AL) amyloidosis, or Waldenstroms macroglobulinemia
* Concurrent intravenous bisphosphonate use more often than once a year
* Prior or ongoing treatment for plasma cell disorder
* Active hepatitis B or C due to risk of infection made worse by study drug
* If subject has human immunodeficiency virus (HIV), they must have a CD4 count \>= 350, no history of acquired immune deficiency syndrome-related illness, and not currently prescribed zidovudine or stavudine
* Subjects may be receiving concomitant low dose corticosteroids (e.g., prednisone up to but no more than 10 mg by mouth daily or its equivalent) for symptom management and comorbid conditions
* Uncontrolled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association \[NYHA\] class III or IV), unstable angina pectoris, cardiac arrhythmia, myocardial infarction in the preceding 6 months, or psychiatric illness/social situations that would limit compliance with study requirements
* Subjects with gastrointestinal disease that may significantly alter the absorption of iberdomide
* Pregnant women are excluded from this study because protocol therapy has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to protocol treatment of the mother, breastfeeding should be discontinued
* Current or prior use of immunosuppressive medication within 14 days prior to the first dose of iberdomide. The following are exceptions to this criterion: intranasal, inhaled, topical or local steroid injections (e.g., intra-articular injection); systemic corticosteroids at physiologic doses that do not exceed 10 mg/day of prednisone or equivalent steroids as premedication for hypersensitivity reactions (e.g, computed tomography \[CT\] scan pre-medications)

Where this trial is running

Atlanta, Georgia

• Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia, United States (Recruiting)

Study contacts

• Principal investigator: Nisha S Joseph, MD — Emory University
• Study coordinator: Nisha S. Joseph, MD

Conditions Smoldering Plasma Cell Myeloma